Pharmaceutical

AltruBio secures $225m for immune checkpoint programme development

AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.

May 23, 2024 - 04:00
AltruBio secures $225m for immune checkpoint programme development
AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.
Read the original article

Tags:

Previous Article

Alvotech and Dr Reddy’s partner to commercialise AVT03

Next Article

Endeavor’s IPF Drug Linked to Improved Lung Function in Phase 2 Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Microparticle analysis: methods and uses in the pharmaceutical industry

Microparticle analysis: methods and uses in the pharmac...

May 10, 2023

Trump surgeon general admits Trump White House made mistakes during Covid

Trump surgeon general admits Trump White House made mis...

Sep 8, 2023

AAIC 2024: Eisai presents positive long-term data with Leqembi

AAIC 2024: Eisai presents positive long-term data with ...

Aug 3, 2024